Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

Abstract: A reservoir for liquid medicament includes a first boundary portion and a second boundary portion forming at least one cavity to receive the medicament. The first boundary portion is flexible, while the second boundary portion is rigid. At least one of the first and second boundary portions is a transparent boundary portion covered by an opaque cover which is at least partially detachable from the transparent boundary portion.

Abstract: The invention provides new heterocyclic compounds having the general formula (IA) wherein A, L, X, Y, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: The present invention provides compounds that cause specifically the degradation of EGFR via the targeted ubiquitination of EGFR protein and subsequent proteasomal degradation. The present compounds are useful for the treatment of various cancers.

Abstract: The invention provides new heterocyclic compounds having the general formula wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1, R2 and R3 are as described herein, pharmaceutically acceptable salts thereof, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: Present invention provides bifunctional compounds that comprise an E3 Ubiquitin Ligase moiety that is linked to a moiety that inhibit EGFR, where the target protein can be proximate to the ubiquitin ligase to effect degradation of said protein. Present compounds are useful for the treatment of various cancers.

Abstract: The invention provides new heterocyclic compounds having the general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: A method for operating a magnetic resonance device is provided. The magnetic resonance device includes a component that has an operating limit in relation to a state parameter. The component uses a protocol to record magnetic resonance data. The protocol includes a magnetic resonance sequence and is described by protocol parameters. A protocol parameter set that, in relation to a protocol section, allows the protocol section to be repeated as often as desired without exceeding the operating limit is provided or determined. The method includes receiving a boost parameter from a user interface. At least for the protocol section, adaptation parameters are determined at least partially automatically based on the boost parameter, such that the desired number of repetitions described by the boost parameter is established while complying with the operating limit. Magnetic resonance data is recorded with the protocol using the determined adaptation parameters.

Abstract: The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

Abstract: The present invention provides compounds which are selective allosteric inhibitors of TMLR, TMLRCS, LR, LACS containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

Abstract: An apparatus for recording the amount of medicament ejected from an injection device includes a processor to receive information from a primary sensor and a secondary sensor and a memory. The primary sensor is configured to detect information displayed or generated by said injection device and to generate output corresponding thereto. The secondary sensor is configured to detect ejection of medicament from said injection device. The processor is configured to process the output generated by the primary sensor and to record in the memory information indicative of an amount of medicament ejected from said injection device only when the processor determines, on the basis of information received from the secondary sensor, that more than a predetermined amount of medicament has been ejected.

Abstract: A supplemental device for attachment to an injection device, the supplemental device is presented having a processor arrangement; and a quantity determiner for determining a quantity of medicament that has been delivered, wherein the quantity determiner has a sensor arranged to detect movement of a drive screw of the injection device during medicament delivery.

Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

Abstract: The disclosure provides a two-chamber carpule comprising two-chambers adapted to be joined together. Each chamber is adapted to contain a medicament component. The carpule further comprises a bevel arranged on a circumference of at least one of the chambers in a transition area. The bevel extends from one chamber to the other chamber.

Abstract: The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.